Limin-Chen-profileDr.Limin Chen, a professor with the Institute of Blood Transfusion (IBT), Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC) and also an affiliated scientist with the University of Toronto, now is the director and chief scientific officer of the center for transfusion-transmitted infectious diseases, IBT, CAMS/PUMC, Member of the American Association for Studies of Liver Diseases (AASLD) and Canadian Association for Studies of Liver (CASL). He got his B Sc in medicine, M Sc in biochemistry and molecular biology from China, PhD in molecular genetics from the University of Toronto. Dr. Chen obtained his postdoctoral training in molecular virology both at the Merck Research Laboratories (West Point, PA, USA) with a prestigious World Health Organization (WHO) Fellowship and at the MGH Harvard Medical School . Currently Dr. Limin Chens research focuses on transfusion-transmitted diseases, such as virus-host interactions of the transfusion-transmitted hepatitis viruses, especially hepatitis C virus (HCV).  He pioneered the work on identification of the response signature that can be used to predict treatment response in HCV infected patients and proposed a novel mechanism on how HCV exploits host innate immune response to benefit its persistent infection and thus resistance to interferon-based therapy. His original publication has been cited for more than 350 times, among which are journals such as Science, Nature Medicine, New England Journal of Medicine, etc.  Dr. Chen is one of the editorial advisory board members for Journal of Infectious Diseases (JID), associate editors for Hepatitis Monthly and Journal of Clinical and Translational Hepatology, editors for more than 10 other scientific journals.  He also serves as ad hoc scientific reviewer for Gastroenterology, Hepatology, Gut, Journal of hepatology, etc. Dr. Chen won various prestigious awards, including World  Health Organization (WHO) Fellowship, Canadian Graduate Scholarship (CGS), National CIHR Research Training Program Fellowship in hepatitis C (NCRTP-HepC) , Best Research Award (Canadian Association for Studies of Liver Diseases, CASL), Presidential Award from Asia-Pacific Association for the studies of Liver Diseases, APASL 2013) and many others.